Maryam Rahman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maryam Rahman has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
Brian L. Hoh
4 shared publicationsWilliam A. Friedman
4 shared publicationsGregory J. A. Murad
Department of Neurosurgery and
3 shared publications- Hassan Azari
School of Podiatric Medicine, Barry University
3 shared publications J Mocco
Department of Neurosurgery, University of Florida, Gainesville, Florida
3 shared publicationsAida Karachi
Preston A. Wells, Jr. Center for Brain Tumor Therapy, UF Brain Tumor Immunotherapy Program, Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, USA
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (5)
Grief in Neurosurgery: Reframing Loss and Identity Through Lived Experience
Grief is an under-recognized yet pervasive experience in neurosurgery, arising not only from the death of patients and loved ones but also from losses related to professional identity, health, and personal relationships. Despite its relevance, grief is often conflated with burnout or overlooked entirely within surgical culture. When personal adversity strikes, such as loss, illness, or major life upheaval, the intensity of neurosurgical practice can amplify these challenges, influencing professional identity, performance, and overall resilience. As the field continues to evolve and diversify, it is increasingly important to foster open dialogue about vulnerability, personal hardship, and life beyond the operating room. This perspective examines how neurosurgeons experience and process loss, distinguishing grief from burnout and resilience, and highlighting the need for institutional and cultural change.
- 16 September 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (5)
Open AccessGrief in Neurosurgery: Reframing Loss and Identity Through Lived Experience
Grief is an under-recognized yet pervasive experience in neurosurgery, arising not only from the death of patients and loved ones but also from losses related to professional identity, health, and personal relationships. Despite its relevance, grief is often conflated with burnout or overlooked entirely within surgical culture. When personal adversity strikes, such as loss, illness, or major life upheaval, the intensity of neurosurgical practice can amplify these challenges, influencing professional identity, performance, and overall resilience. As the field continues to evolve and diversify, it is increasingly important to foster open dialogue about vulnerability, personal hardship, and life beyond the operating room. This perspective examines how neurosurgeons experience and process loss, distinguishing grief from burnout and resilience, and highlighting the need for institutional and cultural change.
- Open Access
- 3 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (16)
Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response
Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and dampen the immune response, negatively affecting patient survival. Therefore, targeting TAMs could address the limitations of current cancer treatments. However, drug development in this area remains limited. The leukocyte-associated Ig-like receptor 1 (LAIR1), also called CD305, is prominently expressed on the surface of TAMs. We have uncovered what we believe to be a previously unrecognized immunosuppressive LAIR1/factor XIII A/collagen IV pathway across various cancer types. Inhibition of LAIR1, either through knockout ( Lair1 –/– ), antibody blockade (anti-Lair1 antibody), or a chimeric antigen receptor (CAR) design (3-in-1 CAR by combining tumor targeting, T cell trafficking, and remodeling of the immunosuppressive TME in 1 CAR construct) provided an enhanced antitumor response. LAIR1 inhibition enhanced peripheral and intratumoral CD8 memory T cell populations, induced a phenotypic shift of M2-like macrophages toward M1 macrophages, and normalized tumor collagen IV and structural components in the TME, facilitating effective tumor–T cell interactions and tumor suppression. Enhanced antitumor responses were observed when Lair1 –/– or anti-Lair1 antibody was used alone or in combination with CAR T cells or when the 3-in-1 CAR T cells were used solely in tumor models resistant to chemotherapy–radiation–programmed cell death protein 1 (PD-1) blockade. These findings position LAIR1 inhibition as a promising strategy for cancer immunotherapies.
- 3 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (16)
Open AccessTargeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response
Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and dampen the immune response, negatively affecting patient survival. Therefore, targeting TAMs could address the limitations of current cancer treatments. However, drug development in this area remains limited. The leukocyte-associated Ig-like receptor 1 (LAIR1), also called CD305, is prominently expressed on the surface of TAMs. We have uncovered what we believe to be a previously unrecognized immunosuppressive LAIR1/factor XIII A/collagen IV pathway across various cancer types. Inhibition of LAIR1, either through knockout ( Lair1 –/– ), antibody blockade (anti-Lair1 antibody), or a chimeric antigen receptor (CAR) design (3-in-1 CAR by combining tumor targeting, T cell trafficking, and remodeling of the immunosuppressive TME in 1 CAR construct) provided an enhanced antitumor response. LAIR1 inhibition enhanced peripheral and intratumoral CD8 memory T cell populations, induced a phenotypic shift of M2-like macrophages toward M1 macrophages, and normalized tumor collagen IV and structural components in the TME, facilitating effective tumor–T cell interactions and tumor suppression. Enhanced antitumor responses were observed when Lair1 –/– or anti-Lair1 antibody was used alone or in combination with CAR T cells or when the 3-in-1 CAR T cells were used solely in tumor models resistant to chemotherapy–radiation–programmed cell death protein 1 (PD-1) blockade. These findings position LAIR1 inhibition as a promising strategy for cancer immunotherapies.
- Open Access
- 7 July 2022
- Published by LIDSEN Publishing Inc in OBM Neurobiology
- Vol. 06 (03) , 1-10
Clival Paraganglioma, Case Report and Literature Review
Paragangliomas are rare tumors that may present with cranial neuropathies when located along the skull base. Supratentorial paragangliomas are less likely to secrete catecholamines but should be worked up, nonetheless. We highlight a case of a female in her fourth decade found to have a petroclival lesion following initial presentation that included one month of tooth pain, dysphagia, diplopia, hoarseness and right hemifacial hypoesthesia. Magnetic resonance imaging of the brain demonstrated a T2 hyperintense lesion favored to be a petroclival meningioma. Pre-operative angiography demonstrated a hypervascular tumor. She underwent a combined presigmoid craniotomy with posterior petrosectomy performed by both neurosurgery and neuro-otology. Pathology demonstrated paraganglioma. She had small volume residual tumor and is planned for continued outpatient radiotherapy. Paragangliomas should be on the differential for skull base lesions. Management paradigm involves multidisciplinary care and a combination of surgical resection and post-operative radiation. In this paper, we discuss underlying pathophysiology as well as appropriate workup and management.
- 7 July 2022
- Published by LIDSEN Publishing Inc in OBM Neurobiology
- Vol. 06 (03) , 1-10
Open AccessClival Paraganglioma, Case Report and Literature Review
Paragangliomas are rare tumors that may present with cranial neuropathies when located along the skull base. Supratentorial paragangliomas are less likely to secrete catecholamines but should be worked up, nonetheless. We highlight a case of a female in her fourth decade found to have a petroclival lesion following initial presentation that included one month of tooth pain, dysphagia, diplopia, hoarseness and right hemifacial hypoesthesia. Magnetic resonance imaging of the brain demonstrated a T2 hyperintense lesion favored to be a petroclival meningioma. Pre-operative angiography demonstrated a hypervascular tumor. She underwent a combined presigmoid craniotomy with posterior petrosectomy performed by both neurosurgery and neuro-otology. Pathology demonstrated paraganglioma. She had small volume residual tumor and is planned for continued outpatient radiotherapy. Paragangliomas should be on the differential for skull base lesions. Management paradigm involves multidisciplinary care and a combination of surgical resection and post-operative radiation. In this paper, we discuss underlying pathophysiology as well as appropriate workup and management.
- Open Access
- 15 April 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (8)
Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma
Tumor Treating Fields (TTFields), an approved therapy for glioblastoma (GBM) and malignant mesothelioma, employ noninvasive application of low-intensity, intermediate-frequency, alternating electric fields to disrupt the mitotic spindle, leading to chromosome missegregation and apoptosis. Emerging evidence suggests that TTFields may also induce inflammation. However, the mechanism underlying this property and whether it can be harnessed therapeutically are unclear. Here, we report that TTFields induced focal disruption of the nuclear envelope, leading to cytosolic release of large micronuclei clusters that intensely recruited and activated 2 major DNA sensors — cyclic GMP-AMP synthase (cGAS) and absent in melanoma 2 (AIM2) — and their cognate cGAS/stimulator of interferon genes (STING) and AIM2/caspase 1 inflammasomes to produce proinflammatory cytokines, type 1 interferons (T1IFNs), and T1IFN-responsive genes. In syngeneic murine GBM models, TTFields-treated GBM cells induced antitumor memory immunity and a cure rate of 42% to 66% in a STING- and AIM2-dependent manner. Using single-cell and bulk RNA sequencing of peripheral blood mononuclear cells, we detected robust post-TTFields activation of adaptive immunity in patients with GBM via a T1IFN-based trajectory and identified a gene panel signature of TTFields effects on T cell activation and clonal expansion. Collectively, these studies defined a therapeutic strategy using TTFields as cancer immunotherapy in GBM and potentially other solid tumors.
- 15 April 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (8)
Open AccessTumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma
Tumor Treating Fields (TTFields), an approved therapy for glioblastoma (GBM) and malignant mesothelioma, employ noninvasive application of low-intensity, intermediate-frequency, alternating electric fields to disrupt the mitotic spindle, leading to chromosome missegregation and apoptosis. Emerging evidence suggests that TTFields may also induce inflammation. However, the mechanism underlying this property and whether it can be harnessed therapeutically are unclear. Here, we report that TTFields induced focal disruption of the nuclear envelope, leading to cytosolic release of large micronuclei clusters that intensely recruited and activated 2 major DNA sensors — cyclic GMP-AMP synthase (cGAS) and absent in melanoma 2 (AIM2) — and their cognate cGAS/stimulator of interferon genes (STING) and AIM2/caspase 1 inflammasomes to produce proinflammatory cytokines, type 1 interferons (T1IFNs), and T1IFN-responsive genes. In syngeneic murine GBM models, TTFields-treated GBM cells induced antitumor memory immunity and a cure rate of 42% to 66% in a STING- and AIM2-dependent manner. Using single-cell and bulk RNA sequencing of peripheral blood mononuclear cells, we detected robust post-TTFields activation of adaptive immunity in patients with GBM via a T1IFN-based trajectory and identified a gene panel signature of TTFields effects on T cell activation and clonal expansion. Collectively, these studies defined a therapeutic strategy using TTFields as cancer immunotherapy in GBM and potentially other solid tumors.
- Open Access
Slow-Cycling Cells in Glioblastoma: A Specific Population in the Cellular Mosaic of Cancer Stem Cells
Glioblastoma (GBM) exhibits populations of cells that drive tumorigenesis, treatment resistance, and disease progression. Cells with such properties have been described to express specific surface and intracellular markers or exhibit specific functional states, including being slow-cycling or quiescent with the ability to generate proliferative progenies. In GBM, each of these cellular fractions was shown to harbor cardinal features of cancer stem cells (CSCs). In this study, we focus on the comparison of these cells and present evidence of great phenotypic and functional heterogeneity in brain cancer cell populations with stemness properties, especially between slow-cycling cells (SCCs) and cells phenotypically defined based on the expression of markers commonly used to enrich for CSCs. Here, we present an integrative analysis of the heterogeneity present in GBM cancer stem cell populations using a combination of approaches including flow cytometry, bulk RNA sequencing, and single cell transcriptomics completed with functional assays. We demonstrated that SCCs exhibit a diverse range of expression levels of canonical CSC markers. Importantly, the property of being slow-cycling and the expression of these markers were not mutually inclusive. We interrogated a single-cell RNA sequencing dataset and defined a group of cells as SCCs based on the highest score of a specific metabolic signature. Multiple CSC groups were determined based on the highest expression level of CD133, SOX2, PTPRZ1, ITGB8, or CD44. Each group, composed of 22 cells, showed limited cellular overlap, with SCCs representing a unique population with none of the 22 cells being included in the other groups. We also found transcriptomic distinctions between populations, which correlated with clinicopathological features of GBM. Patients with strong SCC signature score were associated with shorter survival and clustered within the mesenchymal molecular subtype. Cellular diversity amongst these populations was also demonstrated functionally, as illustrated by the heterogenous response to the chemotherapeutic agent temozolomide. In conclusion, our study supports the cancer stem cell mosaicism model, with slow-cycling cells representing critical elements harboring key features of disseminating cells.
Open AccessSlow-Cycling Cells in Glioblastoma: A Specific Population in the Cellular Mosaic of Cancer Stem Cells
Glioblastoma (GBM) exhibits populations of cells that drive tumorigenesis, treatment resistance, and disease progression. Cells with such properties have been described to express specific surface and intracellular markers or exhibit specific functional states, including being slow-cycling or quiescent with the ability to generate proliferative progenies. In GBM, each of these cellular fractions was shown to harbor cardinal features of cancer stem cells (CSCs). In this study, we focus on the comparison of these cells and present evidence of great phenotypic and functional heterogeneity in brain cancer cell populations with stemness properties, especially between slow-cycling cells (SCCs) and cells phenotypically defined based on the expression of markers commonly used to enrich for CSCs. Here, we present an integrative analysis of the heterogeneity present in GBM cancer stem cell populations using a combination of approaches including flow cytometry, bulk RNA sequencing, and single cell transcriptomics completed with functional assays. We demonstrated that SCCs exhibit a diverse range of expression levels of canonical CSC markers. Importantly, the property of being slow-cycling and the expression of these markers were not mutually inclusive. We interrogated a single-cell RNA sequencing dataset and defined a group of cells as SCCs based on the highest score of a specific metabolic signature. Multiple CSC groups were determined based on the highest expression level of CD133, SOX2, PTPRZ1, ITGB8, or CD44. Each group, composed of 22 cells, showed limited cellular overlap, with SCCs representing a unique population with none of the 22 cells being included in the other groups. We also found transcriptomic distinctions between populations, which correlated with clinicopathological features of GBM. Patients with strong SCC signature score were associated with shorter survival and clustered within the mesenchymal molecular subtype. Cellular diversity amongst these populations was also demonstrated functionally, as illustrated by the heterogenous response to the chemotherapeutic agent temozolomide. In conclusion, our study supports the cancer stem cell mosaicism model, with slow-cycling cells representing critical elements harboring key features of disseminating cells.
- Open Access
- 17 May 2021
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 12, 228
Prolonged survival after laser interstitial thermal therapy in glioblastoma
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Management includes surgical resection followed by chemoradiation, and prognosis remains poor. Surgical resection is not possible for some deep-seated or eloquent tumors. Laser interstitial thermal therapy (LITT) has emerged as a new, minimally invasive surgical option for deep-seated GBM. Case Description: We report a case of newly diagnosed thalamic GBM managed with LITT followed by radiation and chemotherapy. Conclusion: The patient remains well at 50-month post-LITT, indicating a potentially unique durability of LITT treatment in GBM.
- 17 May 2021
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 12, 228
Open AccessProlonged survival after laser interstitial thermal therapy in glioblastoma
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Management includes surgical resection followed by chemoradiation, and prognosis remains poor. Surgical resection is not possible for some deep-seated or eloquent tumors. Laser interstitial thermal therapy (LITT) has emerged as a new, minimally invasive surgical option for deep-seated GBM. Case Description: We report a case of newly diagnosed thalamic GBM managed with LITT followed by radiation and chemotherapy. Conclusion: The patient remains well at 50-month post-LITT, indicating a potentially unique durability of LITT treatment in GBM.
- Open Access
- 1 January 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 151 (1) , 1
Journal of Neuro Oncology: immunotherapy for brain tumors
- 1 January 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 151 (1) , 1
Open AccessJournal of Neuro Oncology: immunotherapy for brain tumors
- Top Cited Papers
- 1 October 2020
- Published by Elsevier in Neurosurgery Clinics of North America
- Vol. 31 (4) , 481-488
Epidemiology of Brain Metastases
- 1 October 2020
- Published by Elsevier in Neurosurgery Clinics of North America
- Vol. 31 (4) , 481-488
Top Cited PapersEpidemiology of Brain Metastases
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi164
PATH-27. IDENTIFYING THE GENETIC SIGNATURE OF RESPONSE IN A PHASE II STUDY OF TUMOR TREATING FIELDS IN RECURRENT GLIOBLASTOMA
Prognosis of relapsed glioblastoma (GBM) is dismal and current treatment fails to provide prolonged survival. Small subsets of patients respond well to some novel therapeutics probably due to the genetic variations of tumors and patients. In the Phase 3 EF-11 recurrent GBM trial, a small subset of patients derived significant benefit from TTFields alone. This proof-of-concept trial [NCT01954576] will study adult patients with relapsed GBM treated with TTFields by genetic analysis of primary and recurrent tumors. Post-hoc correlations will be used between clinical response, mutational analyses and quantitative gene expression to define genomic signatures of response. Whole exome and RNA sequencing will be used to identify genomic signature of responders to TTFields. Fifteen patients with bevacizumab-naïve recurrent GBM and 15 patients with bevacizumab-refractory GBM will be treated with TTFields for 6 and 4 months respectively. Patients will undergo standard brain MRI scans without and with gadolinium contrast and perfusion imaging every 8 weeks. Tissue from the primary tumor at recurrence will be genetically analyzed. Genomic DNA (gDNA) will be extracted from patients tumor and blood samples. Purified gDNA fragments will be used for Illumina sequencing library construction. Certain germ-line variants may contribute to gliomagenesis and be associated with somatic mutations within the tumor and subtypes of GBM more or less sensitive to TTFields. Analyses will be conducted on all patients: bevacizumab-naïve and bevacizumab-refractory GBM separately, and patients with objective radiographic response (complete response + partial response (CR + PR) and stable disease (SD) separately. With 50% bevacizumab-refractory GBM patients, response rate will be significantly higher than the baseline rate of 14%. Using an Exact test with type I error of 0.05 and 80% power, the estimated sample sizes will detect a statistical difference on response rate in the TTFields group compared to historical controls. To-date 4 patients have been enrolled.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi164
PATH-27. IDENTIFYING THE GENETIC SIGNATURE OF RESPONSE IN A PHASE II STUDY OF TUMOR TREATING FIELDS IN RECURRENT GLIOBLASTOMA
Prognosis of relapsed glioblastoma (GBM) is dismal and current treatment fails to provide prolonged survival. Small subsets of patients respond well to some novel therapeutics probably due to the genetic variations of tumors and patients. In the Phase 3 EF-11 recurrent GBM trial, a small subset of patients derived significant benefit from TTFields alone. This proof-of-concept trial [NCT01954576] will study adult patients with relapsed GBM treated with TTFields by genetic analysis of primary and recurrent tumors. Post-hoc correlations will be used between clinical response, mutational analyses and quantitative gene expression to define genomic signatures of response. Whole exome and RNA sequencing will be used to identify genomic signature of responders to TTFields. Fifteen patients with bevacizumab-naïve recurrent GBM and 15 patients with bevacizumab-refractory GBM will be treated with TTFields for 6 and 4 months respectively. Patients will undergo standard brain MRI scans without and with gadolinium contrast and perfusion imaging every 8 weeks. Tissue from the primary tumor at recurrence will be genetically analyzed. Genomic DNA (gDNA) will be extracted from patients tumor and blood samples. Purified gDNA fragments will be used for Illumina sequencing library construction. Certain germ-line variants may contribute to gliomagenesis and be associated with somatic mutations within the tumor and subtypes of GBM more or less sensitive to TTFields. Analyses will be conducted on all patients: bevacizumab-naïve and bevacizumab-refractory GBM separately, and patients with objective radiographic response (complete response + partial response (CR + PR) and stable disease (SD) separately. With 50% bevacizumab-refractory GBM patients, response rate will be significantly higher than the baseline rate of 14%. Using an Exact test with type I error of 0.05 and 80% power, the estimated sample sizes will detect a statistical difference on response rate in the TTFields group compared to historical controls. To-date 4 patients have been enrolled.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi136
IMMU-66. A NOVEL METABOLITE TO INCREASE EFFICACY OF CELLULAR IMMUNOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA
Immune cell migration is critical for cellular immunotherapy efficacy in the treatment of glioblastoma (GBM). Sarcosine is a non-toxic metabolite that is associated with a migratory phenotype in prostate cancer cells. We utilized sarcosine to increase migration of dendritic cells (DC) and T cells to increase efficacy of cellular immunotherapy. HYPOTHESIS: Sarcosine increases cellular migration and will improve tumor outcomes when combined with cellular immunotherapy platforms in the treatment of GBM. DC and T cell migration was evaluated in vitro using transwell plates and in vivo using flowcytometry and immunofluorescence microscopy. The impact of sarcosine loaded cells on tumor outcomes was measured by testing a DC vaccine platform in the treatment of murine tumor models. Genomic expression of cytokines on sarcosine treated cells was tested using RT-PCR. Cells were efficiently loaded with sarcosine by simply adding sarcosine to the culture media (20mM). DCs and T cells loaded with sarcosine demonstrated increased migration in vitro (p<0.0001). Mice treated with DC vaccination in the setting of sarcosine demonstrated significantly increased DC migration to draining lymph nodes and spleens (p<0.05). Gene expression analysis demonstrated that sarcosine caused upregulation of cytokines (IFNg,Xcl1,Fasl,Csf2,CCL19,Bmp2,IFNa2 and IL27) and downregulation of other cytokines (Ccl22,IL1b,Cxcl3,Ccl5,IL9 and IL18)(p<0.05). Vaccination with sarcosine loaded OVA-DCs led to increased proliferation of antigen specific T cells compared to regular OVA-DC vaccination (p<0.05). B16F10-OVA tumor bearing animals treated with sarcosine loaded OVA-DC vaccines had significantly reduced tumor growth and prolonged survival compared to animals treated with OVA-DC vaccines without sarcosine (p<0.0001). Sarcosine loaded DC vaccines resulted in suppressed tumor growth and improved survival in a murine model. These effects are partially mediated by changes in cytokine expression in sarcosine loaded DCs. Further experiments testing sarcosine loaded T cells and the mechanism of increased migration in sarcosine loaded immune cells are underway.
- 5 November 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_6) , vi136
IMMU-66. A NOVEL METABOLITE TO INCREASE EFFICACY OF CELLULAR IMMUNOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA
Immune cell migration is critical for cellular immunotherapy efficacy in the treatment of glioblastoma (GBM). Sarcosine is a non-toxic metabolite that is associated with a migratory phenotype in prostate cancer cells. We utilized sarcosine to increase migration of dendritic cells (DC) and T cells to increase efficacy of cellular immunotherapy. HYPOTHESIS: Sarcosine increases cellular migration and will improve tumor outcomes when combined with cellular immunotherapy platforms in the treatment of GBM. DC and T cell migration was evaluated in vitro using transwell plates and in vivo using flowcytometry and immunofluorescence microscopy. The impact of sarcosine loaded cells on tumor outcomes was measured by testing a DC vaccine platform in the treatment of murine tumor models. Genomic expression of cytokines on sarcosine treated cells was tested using RT-PCR. Cells were efficiently loaded with sarcosine by simply adding sarcosine to the culture media (20mM). DCs and T cells loaded with sarcosine demonstrated increased migration in vitro (p<0.0001). Mice treated with DC vaccination in the setting of sarcosine demonstrated significantly increased DC migration to draining lymph nodes and spleens (p<0.05). Gene expression analysis demonstrated that sarcosine caused upregulation of cytokines (IFNg,Xcl1,Fasl,Csf2,CCL19,Bmp2,IFNa2 and IL27) and downregulation of other cytokines (Ccl22,IL1b,Cxcl3,Ccl5,IL9 and IL18)(p<0.05). Vaccination with sarcosine loaded OVA-DCs led to increased proliferation of antigen specific T cells compared to regular OVA-DC vaccination (p<0.05). B16F10-OVA tumor bearing animals treated with sarcosine loaded OVA-DC vaccines had significantly reduced tumor growth and prolonged survival compared to animals treated with OVA-DC vaccines without sarcosine (p<0.0001). Sarcosine loaded DC vaccines resulted in suppressed tumor growth and improved survival in a murine model. These effects are partially mediated by changes in cytokine expression in sarcosine loaded DCs. Further experiments testing sarcosine loaded T cells and the mechanism of increased migration in sarcosine loaded immune cells are underway.